Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Share News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cambridge University innovation investor raises 75 million pounds

Fri, 19th Aug 2016 09:23

LONDON, Aug 19 (Reuters) - Cambridge Innovation Capital,which commercializes technology and healthcare research fromCambridge University, has raised 75 million pounds ($98 million)from investors, including for the first time Woodford InvestmentManagement.

CIC, founded in 2013, has already invested 33 million poundsin 13 technology and healthcare innovations, such as a companybuilding robots to do keyhole surgery and a drug developer thattargets RNA-modifying enzymes to treat cancer.

The new capital has come from fund manger Neil Woodford'scompany, Winton Ventures and the Oman Investment Fund as well asexisting shareholders including Cambridge-based chip designerARM Holdings and IP Group, CIC said on Friday.

Chief Executive Victor Christou said CIC had madesignificant progress in commercializing science stemming fromCambridge University and other local institutions in theCambridge Cluster, which he said was "one of the richest seamsof scientific and technological innovation in the world".

CIC is following in the footsteps of Imperial InnovationsGroup and its investor IP Group, both of which providecapital and commercial expertise to help researcherscommercialize research from Britain's world class universities.

($1 = 0.7620 pounds) (Reporting by Paul Sandle; editing by Susan Thomas)

More News
27 Jul 2015 07:41

Imperial Innovations Makes Further Investment In Concirrus

Read more
14 Jul 2015 07:38

Imperial Innovations Gets GBP50 Million European Investment Bank Loan

Read more
2 Jul 2015 23:01

For first time, gene therapy shows promise in cystic fibrosis

By Kate Kelland LONDON, July 3 (Reuters) - Scientists conducting a major trial of a therapy that replaces the faulty gene responsible for cystic fibrosis say the treatment has showed significant benefit for the first time in patients' lung function. The technique, developed with the t

Read more
2 Jul 2015 09:49

Imperial Innovations and Mercia Technologies invest in aluminium business

AIM listed firms Imperial Innovations and Mercia Technologies have together provided £4m to aluminium business Impression Technologies. The duo invested £2.5m and £1.5m respectively in the firm which makes aluminium components for the transport sector. The investment brings Imperial Innovation's s

Read more
2 Jul 2015 07:03

Imperial Innovations And Mercia Add To Impression Technologies Stakes

Read more
1 Jul 2015 06:57

Imperial Innovations' Veryan Medical Enrols Subject For MIMICS-2 Study

Read more
30 Jun 2015 16:26

Imperial Innovations invests £3m in Abingdon, brings stake to over 30%

British technology transfer and commercialisation company Imperial Innovations Group said it has invested £3m in portfolio company Abingdon Health. On Tuesday, the London-listed group said that, along with existing investors, it had invested £2.5m in Abingdon and now holds a 33.7% stake in the busin

Read more
30 Jun 2015 07:31

LONDON BRIEFING: Shares Ignore Positive Asian Session To Open Lower

Read more
30 Jun 2015 06:52

Imperial Innovations Leads Funding Round For Abingdon Health

Read more
25 Jun 2015 10:17

London mayor suggests $15 bln 'megafund' to boost biotech

LONDON, June 25 (Reuters) - Banks, investors and big drug companies should consider creating a 10-billion-pound ($15.7 billion) "megafund" to help biotech firms in London and across Britain compete with U.S. rivals, London mayor Boris Johnson said on Thursday. Britain is a leader in academi

Read more
3 Jun 2015 07:23

LONDON MORNING BRIEFING: Merlin Entertainments Hit By Coaster Crash

Read more
3 Jun 2015 06:48

Imperial Innovations Commits Funds To Antibiotics Developer Auspherix

Read more
29 May 2015 15:31

Imperial Innovations' portfolio company appoints new executive chairman

Technology investment group Imperial Innovations Group has appointed Paolo Paoletti as executive chairman of its portfolio company Kesios Therapeutics. London-based Kesios, which develops novel therapeutics for cancer treatments, was created to develop and commercialise certain research from the Dep

Read more
26 May 2015 07:26

LONDON MORNING BRIEFING: Ryanair, Royal Mail Stand Out From Flat Open

Read more
26 May 2015 06:38

Imperial Innovations Sells Stake In Epigeum For GBP1.9 Million

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.